Bafna Pharmaceuticals Ltd

Bafna Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Bafna Pharmaceuticals Ltd

₹ 89.2 -0.94%
04 Jul - close price
bafnapharma.com BSE: 532989 NSE: BAFNAPH
About

Incorporated in 1981, Bafna Pharmaceuticals
Ltd manufactures finished pharmaceutical formulations[1]

Key Points

Product Profile:[1][2][3]
Company is manufacturing over 336
licensed pharmaceutical formulations
and has globally registered 78 of its
products viz. Afenac-p Tab, Afenac-th
Tab, finished solid oral and liquid oral
dosage forms of Betalactam and Non – Betalactam and Cephalosporin products

Website BSE NSE
  • Market Cap ₹ 211 Cr.
  • Current Price ₹ 89.2
  • High / Low ₹ 95.0 / 67.8
  • Stock P/E 33.5
  • Book Value ₹ 35.8
  • Dividend Yield 0.00 %
  • ROCE 8.28 %
  • ROE 7.61 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Tax rate seems low
  • Company has a low return on equity of 10.9% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
14.98 16.93 21.96 34.22 42.24 41.95 40.68 28.44 41.40 33.29 40.32 33.19 39.06
15.36 15.27 19.42 31.18 34.62 35.66 36.67 30.51 38.51 32.08 36.53 30.13 35.95
Operating Profit -0.38 1.66 2.54 3.04 7.62 6.29 4.01 -2.07 2.89 1.21 3.79 3.06 3.11
OPM % -2.54% 9.81% 11.57% 8.88% 18.04% 14.99% 9.86% -7.28% 6.98% 3.63% 9.40% 9.22% 7.96%
1.04 1.30 0.64 1.93 0.26 1.87 0.16 0.98 0.52 0.16 1.02 0.18 -0.76
Interest 0.21 0.31 0.45 0.58 0.70 0.60 0.44 0.58 0.68 0.65 0.62 0.64 0.82
Depreciation 1.40 1.29 1.12 1.40 1.53 1.21 1.24 1.27 1.27 1.44 1.58 1.66 0.22
Profit before tax -0.95 1.36 1.61 2.99 5.65 6.35 2.49 -2.94 1.46 -0.72 2.61 0.94 1.31
Tax % 0.00% 0.00% 0.00% 0.00% 4.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
-0.95 1.36 1.61 3.00 5.37 6.35 2.48 -2.94 1.46 -0.72 2.62 0.95 1.31
EPS in Rs -0.40 0.57 0.68 1.27 2.27 2.68 1.05 -1.24 0.62 -0.30 1.11 0.40 0.55
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
177 100 85 65 46 44 42 71 85 115 152 146
156 116 82 70 81 57 41 61 73 100 141 135
Operating Profit 21 -16 3 -5 -35 -13 1 10 12 16 11 11
OPM % 12% -16% 3% -8% -77% -30% 3% 14% 14% 14% 7% 8%
1 40 1 1 31 0 -23 1 -0 3 4 1
Interest 12 12 12 11 7 2 0 1 1 2 2 3
Depreciation 8 5 4 4 4 3 3 4 5 5 5 5
Profit before tax 2 6 -13 -19 -14 -18 -25 6 5 12 7 4
Tax % 40% -0% -3% -4% 15% 8% 0% 0% 0% 2% 0% 0%
1 6 -12 -18 -16 -20 -25 6 5 11 7 4
EPS in Rs 0.72 3.28 -6.53 -9.90 -6.95 -8.34 -106.53 2.46 2.21 4.79 3.11 1.75
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 4%
5 Years: 28%
3 Years: 20%
TTM: -4%
Compounded Profit Growth
10 Years: 8%
5 Years: 40%
3 Years: -5%
TTM: -13%
Stock Price CAGR
10 Years: 13%
5 Years: 32%
3 Years: -8%
1 Year: 1%
Return on Equity
10 Years: -10%
5 Years: 11%
3 Years: 11%
Last Year: 8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 19 19 19 19 24 24 2 24 24 24 24 24
Reserves 50 53 41 26 17 -3 49 33 38 50 57 61
99 64 80 82 47 46 3 15 11 23 24 28
54 50 45 40 40 54 17 14 17 33 42 40
Total Liabilities 223 185 185 167 128 121 71 86 90 130 148 153
63 49 47 43 40 37 35 36 39 40 40 59
CWIP 0 0 0 0 0 0 0 1 0 2 12 7
Investments 1 18 18 18 1 1 0 0 0 0 0 0
158 118 120 106 86 82 36 50 51 88 95 87
Total Assets 223 185 185 167 128 121 71 86 90 130 148 153

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1 9 -3 14 -7 -1 -34 -14 10 5 9 22
-5 56 -1 -8 38 4 33 -5 -7 -7 -15 -21
-14 -66 4 -5 -31 -2 7 12 -5 10 -1 1
Net Cash Flow -18 -0 0 -0 0 0 6 -7 -2 8 -6 2

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 192 303 291 302 195 208 52 49 63 130 109 101
Inventory Days 78 66 92 118 102 122 208 154 185 129 125 127
Days Payable 116 149 169 164 265 517 229 107 113 165 149 140
Cash Conversion Cycle 155 220 214 255 31 -188 31 96 135 94 84 88
Working Capital Days 204 250 320 207 79 -16 89 172 148 150 126 109
ROCE % 9% -13% -0% -6% -35% -21% -3% 10% 11% 16% 9% 8%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
90.12% 90.00% 90.01% 89.99% 89.99% 88.73% 88.42% 88.29% 88.29% 88.29% 88.29% 75.00%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8.53%
9.88% 10.00% 9.98% 10.00% 10.00% 11.27% 11.57% 11.70% 11.71% 11.70% 11.70% 16.47%
No. of Shareholders 7,2237,2757,1997,1206,9927,3547,3677,5397,3917,2957,2147,142

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings